Company Overview and News

0
Extendicare: What Will It Take To Improve Its Business Outlook?

2018-05-29 seekingalpha
Extendicare will have to significantly expand its higher margin retirement living segment in order to improve its business outlook.
SIA SIA.DB EXE EXETF CWSRF

0
Extendicare Announces 2018 First Quarter Results

2018-05-10 globenewswire
MARKHAM, Ontario, May 10, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) today reported results for the three months ended March 31, 2018. Results are presented in Canadian dollars unless otherwise noted.
EXE

0
Extendicare Announces Closing of Underwriters' $16.5 Million Over-Allotment Option of 5.00% Convertible Debentures

2018-04-25 globenewswire
MARKHAM, Ontario, April 25, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced today that it has issued an additional $16.5 million aggregate principal amount of its 5.00% convertible unsecured subordinated debentures due April 30, 2025 (the “Debentures”) following the exercise in full of the over-allotment option granted to the syndicate of underwriters in connection with the Company's recent public offering (the “Offering”) of $110 million aggregate principal amount of the Debentures, which closed on April 17, 2018.
EXE

0
Extendicare Completes $110 million Offering of 5.00% Convertible Debentures

2018-04-17 globenewswire
MARKHAM, Ontario, April 17, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced today the closing of its previously announced public offering (the “Offering”) of $110 million aggregate principal amount of 5.00% convertible unsecured subordinated debentures due April 30, 2025 (the “Debentures”), which are convertible, at the option of the holder, into common shares of the Company at a conversion price of $12.
EXE

0
Extendicare Announces April 2018 Dividend of C$0.04 per Share

2018-04-16 globenewswire
MARKHAM, Ontario, April 16, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of April 2018, which is payable on May 15, 2018 to shareholders of record at the close of business on April 30, 2018. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).
EXE

0
Extendicare Completes Acquisition of Lynde Creek Retirement Community

2018-04-11 globenewswire
MARKHAM, Ontario and ETOBICOKE, Ontario , April 11, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) today announced that it has completed the previously disclosed acquisition from the Canadian Baptists of Ontario and Quebec Foundation of Lynde Creek Retirement Community for a cash purchase price of $34.5 million, subject to customary closing adjustments.
EXE

0
Extendicare Announces Timing of 2018 First Quarter Results and Conference Call

2018-04-10 globenewswire
MARKHAM, Ontario, April 10, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced today that it plans to release its financial results for the first quarter of 2018, after market close on Thursday, May 10, 2018. A conference call hosted by Tim Lukenda, President and Chief Executive Officer and Elaine Everson, Vice President and Chief Financial Officer will be held on May 11, 2018, at 11:00 a.
EXE

0
Extendicare Announces Public Offering of $110 Million of Convertible Debentures and Redemption of Its Series 2012 6.00% Convertible Debentures

2018-03-26 globenewswire
MARKHAM, Ontario, March 26, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced today that it has reached an agreement with a syndicate of underwriters led by RBC Capital Markets (the “Underwriters”) to issue to the public, subject to regulatory approval, on a bought deal basis, $110 million aggregate principal amount of 5.00% convertible unsecured subordinated debentures of the Company due April 30, 2025 (the “Debentures”) with a conversion price of $12.
EXE

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:EXE / Extendicare Inc on message board site Silicon Investor.

Exelixis, Inc. (EXEL) American MultiPlexer (AMUT) -- Cheap Now, But for How Long
EXETER RESOURCE CORPORATION (XRC:TSX-V) (EXRCF-OTC) (SWY.TO) Executes Mandate Letter With Lead Arrangers for Ren
Executive Compensation NEXEN--NXY on the TSE
PRXL - Parexel International Fidelity Execution Problems
Complacency Indexes LXNT: Lexent, Inc.